Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
9/16/2026
Impact: 50
Healthcare
BTIG raised the price target for Rapport Therapeutics Inc (NASDAQ:RAPP) from $65 to $75 while maintaining a Buy rating, with shares closing at $42.68. This indicates a potential upside of approximately 76%. Other notable changes include UBS upgrading Union Pacific Corp (NYSE:UNP) from Neutral to Buy with a new price target of $339, and Barclays downgrading Cellectis SA (NASDAQ:CLLS) from Overweight to Underweight with a reduced price target of $1.30.
AI summary, not financial advice
Share: